These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20826338)

  • 1. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.
    Correia BE; Ban YE; Holmes MA; Xu H; Ellingson K; Kraft Z; Carrico C; Boni E; Sather DN; Zenobia C; Burke KY; Bradley-Hewitt T; Bruhn-Johannsen JF; Kalyuzhniy O; Baker D; Strong RK; Stamatatos L; Schief WR
    Structure; 2010 Sep; 18(9):1116-26. PubMed ID: 20826338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10E8-like neutralizing antibodies against HIV-1 induced using a precisely designed conformational peptide as a vaccine prime.
    Yu Y; Tong P; Li Y; Lu Z; Chen Y
    Sci China Life Sci; 2014 Jan; 57(1):117-27. PubMed ID: 24369352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.
    Brunel FM; Zwick MB; Cardoso RM; Nelson JD; Wilson IA; Burton DR; Dawson PE
    J Virol; 2006 Feb; 80(4):1680-7. PubMed ID: 16439525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.
    Cardoso RM; Brunel FM; Ferguson S; Zwick M; Burton DR; Dawson PE; Wilson IA
    J Mol Biol; 2007 Feb; 365(5):1533-44. PubMed ID: 17125793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
    Cardoso RM; Zwick MB; Stanfield RL; Kunert R; Binley JM; Katinger H; Burton DR; Wilson IA
    Immunity; 2005 Feb; 22(2):163-73. PubMed ID: 15723805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
    Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene.
    Sun Z; Zhu Y; Wang Q; Ye L; Dai Y; Su S; Yu F; Ying T; Yang C; Jiang S; Lu L
    Emerg Microbes Infect; 2016 Jun; 5(6):e65. PubMed ID: 27329850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elicitation of structure-specific antibodies by epitope scaffolds.
    Ofek G; Guenaga FJ; Schief WR; Skinner J; Baker D; Wyatt R; Kwong PD
    Proc Natl Acad Sci U S A; 2010 Oct; 107(42):17880-7. PubMed ID: 20876137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies.
    Zhu C; Dukhovlinova E; Council O; Ping L; Faison EM; Prabhu SS; Potter EL; Upton SL; Yin G; Fay JM; Kincer LP; Spielvogel E; Campbell SL; Benhabbour SR; Ke H; Swanstrom R; Dokholyan NV
    Nat Commun; 2019 Feb; 10(1):948. PubMed ID: 30814513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
    Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
    Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design.
    Correia BE; Ban YE; Friend DJ; Ellingson K; Xu H; Boni E; Bradley-Hewitt T; Bruhn-Johannsen JF; Stamatatos L; Strong RK; Schief WR
    J Mol Biol; 2011 Jan; 405(1):284-97. PubMed ID: 20969873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited conformational flexibility in the paratope may be responsible for degenerate specificity of HIV epitope recognition.
    Bhowmick A; Salunke DM
    Int Immunol; 2013 Feb; 25(2):77-90. PubMed ID: 22968994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.
    Wahome N; Pfeiffer T; Ambiel I; Yang Y; Keppler OT; Bosch V; Burkhard P
    Chem Biol Drug Des; 2012 Sep; 80(3):349-57. PubMed ID: 22650354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
    McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
    Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.